Last reviewed · How we verify
Targin
At a glance
| Generic name | Targin |
|---|---|
| Also known as | Oxycodone and Naloxone, Oxycodonhydrochlorid and naloxone hydrochloride dihydrate |
| Sponsor | Mundipharma Korea Ltd |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Pain Relief After Corneal Collagen Cross-Linking (EARLY_PHASE1)
- Comparison Between Oxycodone and Pregabalin as Preemptive Analgesia (PHASE2, PHASE3)
- NanaBis™ an Oro-buccal Administered delta9-Tetrahydrocannabinol (d9-THC) & Cannabidiol (CBD) Medicine for the Management of Bone Pain From Metastatic Cancers (PHASE3)
- Targin® for Chronic Pain Management in Patients With Spinal Cord Injury (PHASE4)
- Efficacy and Safety of Oxycodone/Naloxone (Targin®) in Persistent Moderate to Severe Low Back Pain Following NSAIDs Treatment (PHASE4)
- Determine the Safety and Efficacy of Oxy/Nal Tablets Compared to Oxy PR in Subjects With Cancer Pain (PHASE3)
- OXN PR Tablet 5/2.5 mg and20/10 mg PK Study in Chinese Moderate to Severe Chronic Non-malignant Patients (PHASE1)
- A Study to Evaluate Efficacy and Safety of Oxycodone/Naloxone Compared to OxyContin in Korean Cancer Patients (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Targin CI brief — competitive landscape report
- Targin updates RSS · CI watch RSS
- Mundipharma Korea Ltd portfolio CI